Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Unveils ‘Long Overdue’ Membership Roles

Two Executive Promotions Will Help ‘Put Membership Front And Center’

Executive Summary

The US Association for Accessible Medicines has for the first time appointed two member-focused roles within its organization, as long-serving policy executive Christine Simmon was also handed a promotion.

You may also be interested in...



Who’s Hired? Another Viatris Executive Joins Neuraxpharm

Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.

GDUFA III Talks Completed

Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.

Who’s Hired? BIO’s Duncan Joins AAM

The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer.  Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel